Table 1_A population-based study of social demographic factors, associated diseases, and herpes zoster ophthalmicus in Taiwan.docx by Chia-Yi Lee (2037286)

“…</p>Results<p>Patients with systemic diseases (hypertension, diabetes, hyperlipidaemia, etc.) had significantly higher ORs for HZO development. Patients whose monthly income was >NT$ 30,000 and patients residing in southern Taiwan had increased odds of developing HZO; however, patients residing in northern Taiwan, metropolitans, or satellite cities, and being public servants (military, civil, teaching staff, etc.) had decreased odds of developing HZO.…”

Table 7_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Data Sheet 6_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 4_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Framework synthesis of zinc scale-up programs. by Keith Beam (20700854)

“…Our findings demonstrate the long-term success of the SUZY project and provide insights into best practices for impactful zinc scale-up programs including significant pre-launch implementation research addressing key knowledge gaps and partnering with research organizations. …”

Table 6_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 10_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Data Sheet 9_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Data Sheet 7_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 9_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Data Sheet 8_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 5_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 2_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Data Sheet 5_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Evaluation of disparities in zinc coverage. by Keith Beam (20700854)

“…Our findings demonstrate the long-term success of the SUZY project and provide insights into best practices for impactful zinc scale-up programs including significant pre-launch implementation research addressing key knowledge gaps and partnering with research organizations. …”

Data Sheet 11_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Data Sheet 2_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 8_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 1_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. …”

Table 1_Real-world first-line serplulimab therapy for advanced esophageal cancer: effectiveness, safety, and clinical implications.docx by Fei Yan (128878)

“…Objective<p>The phase III ASTRUM-007 trial demonstrated significant clinical benefit in patients with PD-L1-positive esophageal squamous cell carcinoma (ESCC) treated with first-line serplulimab plus chemotherapy. …”